GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lee's Pharmaceutical Holdings Ltd (OTCPK:LPCUF) » Definitions » Capex-to-Operating-Cash-Flow

LPCUF (Lee's Pharmaceutical Holdings) Capex-to-Operating-Cash-Flow : 1.05 (As of Jun. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Lee's Pharmaceutical Holdings Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Lee's Pharmaceutical Holdings's Capital Expenditure for the six months ended in Jun. 2024 was $-7.96 Mil. Its Cash Flow from Operations for the six months ended in Jun. 2024 was $7.55 Mil.

Hence, Lee's Pharmaceutical Holdings's Capex-to-Operating-Cash-Flow for the six months ended in Jun. 2024 was 1.05.


Lee's Pharmaceutical Holdings Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Lee's Pharmaceutical Holdings's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lee's Pharmaceutical Holdings Capex-to-Operating-Cash-Flow Chart

Lee's Pharmaceutical Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.90 1.64 1.76 0.75 1.45

Lee's Pharmaceutical Holdings Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 3.72 2.22 1.03 1.05

Competitive Comparison of Lee's Pharmaceutical Holdings's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Lee's Pharmaceutical Holdings's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lee's Pharmaceutical Holdings's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lee's Pharmaceutical Holdings's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Lee's Pharmaceutical Holdings's Capex-to-Operating-Cash-Flow falls into.



Lee's Pharmaceutical Holdings Capex-to-Operating-Cash-Flow Calculation

Lee's Pharmaceutical Holdings's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-20.45) / 14.095
=1.45

Lee's Pharmaceutical Holdings's Capex-to-Operating-Cash-Flow for the quarter that ended in Jun. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-7.96) / 7.551
=1.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lee's Pharmaceutical Holdings  (OTCPK:LPCUF) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Lee's Pharmaceutical Holdings Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Lee's Pharmaceutical Holdings's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Lee's Pharmaceutical Holdings Business Description

Traded in Other Exchanges
Address
Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.

Lee's Pharmaceutical Holdings Headlines

No Headlines